Improved Survival with MEK Inhibition in BRAF-Mutated Melanoma

Keith T. Flaherty, Caroline Robert, Peter Hersey, +22

New England Journal of Medicine

Improved survival with MEK Inhibition in BRAF-mutated melanoma for the METRIC Study Group

Keith T. Flaherty, Caroline Robert, Peter Hersey, +16

Zurich Open Repository and Archive (University of Zurich)

A randomized phase II study of the MEK1/MEK2 inhibitor trametinib (GSK1120212) compared with docetaxel in KRAS-mutant advanced non-small-cell lung cancer (NSCLC)

George R. Blumenschein, Egbert F. Smit, David Planchard, +16

Annals of Oncology

Non-small-cell Lung CancerMedicinePharmacologyPathologyCancer Cell Biology +8

Activity of PXD101, a histone deacetylase inhibitor, in preclinical ovarian cancer studies

Xiaozhong Qian, William J. LaRochelle, Gulshan Ara, +6

Molecular Cancer Therapeutics

The impact of endometrioma and laparoscopic cystectomy on serum anti-Müllerian hormone levels

Yuh‐Ming Hwu, Frank Wu, Sheng‐Hsiang Li, +3

Reproductive Biology and Endocrinology

Recombinant Human FIZZ3/Resistin Stimulates Lipolysis in Cultured Human Adipocytes, Mouse Adipose Explants, and Normal Mice

Tatiana Ort, Anibal A. Arjona, John R. MacDougall, +5

Endocrinology

Metabolic DisorderMetabolic RemodelingInsulin SignalingObesityMetabolic Syndrome +18

Dual trigger with gonadotropin releasing hormone agonist and human chorionic gonadotropin significantly improves live birth rate for women with diminished ovarian reserve

Ming-Huei Lin, Frank Wu, Yuh‐Ming Hwu, +3

Reproductive Biology and Endocrinology

Platelet-derived growth factor D: tumorigenicity in mice and dysregulated expression in human cancer.

William J. LaRochelle, Michael Jeffers, José R. F. Corvalán, +14

PubMed

Dysregulated ExpressionImmunologyPdgf DPathologyCell Proliferation +15

Discovery of an Orally Available Diazabicyclooctane Inhibitor (ETX0282) of Class A, C, and D Serine β-Lactamases

Thomas F. Durand-Réville, Janelle Comita-Prevoir, Jing Zhang, +17

Journal of Medicinal Chemistry

Functional and symptom impact of trametinib versus chemotherapy in BRAF V600E advanced or metastatic melanoma: quality-of-life analyses of the METRIC study

Dirk Schadendorf, Mayur M. Amonkar, Mohammed Milhem, +18

Annals of Oncology

Trametinib Versus ChemotherapyOncologyCancer ManagementMelanomaMetastatic Melanoma +5